Gujral S, Puar M, Ranka N
Indian J Physiol Pharmacol. 1978 Jul-Sep;22(3):279-84.
SRC-3605, N-N-bis-P-chlorophenyl 3-p-tolyl glutaric acid diamide, was studied for its hypocholesterolaemic effect on serum and liver cholesterol in hypercholesterolaemic weanling and adult female rats. Weanlings were administered doses of SRC-3605 ranging from 100 to 300 mg/kg body weight for 4 or 8 consecutive days. The greatest hypocholesterolaemic effect was observed with doses of 150, 200 and 250 mg, although a progressive decreases in serum cholesterol was noted with increasing doses. Hepatic cholesterol decreases supported the serum data, but were inconsistent. Hypercholesterolaemic adult animals received 50, 100, 150 or 200 mg/kg body weight of either SRC-3605 or clofibrinic acid for 4 days. A decrease in serum cholesterol levels was observed only with the 200 mg SRC-3605. No clear-cut influence of the either compounds was found on hepatic cholesterol. The results indicated that SRC-3605 possesses the property to reduce both serum and liver cholesterol in hypocholesterolaemic weanling female rats.
研究了SRC - 3605(N - N - 双 - 对氯苯基 - 3 - 对甲苯基戊二酸二酰胺)对高胆固醇血症断奶幼鼠和成年雌性大鼠血清及肝脏胆固醇的降胆固醇作用。给断奶幼鼠连续4天或8天给予剂量范围为100至300毫克/千克体重的SRC - 3605。观察到剂量为150、200和250毫克时降胆固醇效果最佳,不过随着剂量增加血清胆固醇呈逐渐下降趋势。肝脏胆固醇的降低支持了血清数据,但并不一致。给高胆固醇血症成年动物连续4天给予50、100、150或200毫克/千克体重的SRC - 3605或氯贝酸。仅在给予200毫克SRC - 3605时观察到血清胆固醇水平下降。未发现这两种化合物对肝脏胆固醇有明确影响。结果表明,SRC - 3605具有降低高胆固醇血症断奶雌性大鼠血清和肝脏胆固醇的特性。